PROFILAKTIKA TROMBOEMBOLIChESKIKh OSLOZhNENIY U PATsIENTOV S FIBRILLYaTsIEY PREDSERDIY


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Identification of the patients at high risk for a stroke, with subsequent preventive drug treatment allows to reduce the incidence of stroke. The article presents an overview of current guidelines for management of patients with atrial fibrillation (AF) on the example of a specific clinical case. For the majority of patients with nonvalvular AF, new oral anticoagulants are preferred with respect to vitamin K antagonists; they have similar efficacy, favorable safety profile and do not require selection of maintenance dose and subsequent monitoring of coagulation system. According to a meta-analysis of clinical studies, rivaroxaban has benefits for patients at high risk of coronary events. Comfortable reception mode provides high patient’s compliance to the treatment.

Full Text

Restricted Access

References

  1. http://www.mgzt.ru/article/360
  2. Wolf P.A., Abbott R.D., Kannel W.B. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991; 22(8): 983-88.
  3. Воробьев П. Тромбозы, тромбоэмболии и старение. Врач. 2012; 5: 2-5.
  4. Wyse D.G., Waldo A.L., DiMarco J.P., et al. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators N. Engl. J. Med. 2002; 347: 1825-33.
  5. Hart R.G., Pearce L.A., Aguilar M.I. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann. Intern. Med. 2007; 146(12): 857-67.
  6. The ACTIVE Writing Group on behalf of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006; 367: 1903-12.
  7. Aguilar M.I., Hart R., Pearce L.A. Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks. Cochrane Database Syst Rev. 2007; 8(3).
  8. Сычев Д.А. Как сделать терапию варфарином максимально эффективной и безопасной с позиции клинического фармаколога? Сердце: Журнал для практикующих врачей. Т. 11. 2012; 5(67): 264-71.
  9. Munir Pirmohamed et al. A Randomized Trial of Genotype-Guided Dosing of Warfarin. N. Engl. J. Med. 2013; 369: 2294-303.
  10. www.warfarindosing.com
  11. Budnitz D.S., Lovegrove M.C., Shehab N., Richards C.L. Emergency hospitalizations for adverse drug events in older Americans. N. Engl. J. Med. 2011; 365: 2002-12.
  12. Диагностика и лечение фибрилляции предсердий. Российский кардиологический журнал. 2013; 4(102): 1-100. Приложение 3.
  13. Lip G.Y., et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation. Chest. 2010; 137(2): 263-72.
  14. Lip G.Y., et al. Identifying patients at high risk for stroke despite anticoagulation: a comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort. Stroke. 2010; 41 (12): 2731 -38.
  15. Olesen B.J. et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ 2011; 342.
  16. Pisters R., et al. A Novel User-Friendly Score (HAS-BLED) To Assess 1 - Year Risk of Major Bleeding in Patients With Atrial Fibrillation: Euro Heart Survey Chest. 2010; 138(5): 1093-110.
  17. Connolly S.J. et al. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. N. Engl. J. Med. 2009; 361: 1139-51.
  18. Patel M.R., et al. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). J, Am, Coll, Cardiol. 2013; 61 (6): 651 -58.
  19. Easton J.D. et al. Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the Aristotle trial. Lancet. Neurol. 2012; 11(6): 503-11.
  20. Mant J., et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet. 2007; 370(9586): 493-503 Yearly risk of extracranial haemorrhage was 1.4% (warfarin) versus 1.6% (aspirin) (relative risk 0.87, 0.43-1.73; absolute risk reduction 0,2 %, -0,7 to 1,2.
  21. Uchino K., Hernandez A.V. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med. 2012; 12; 172(5): 397-402.
  22. Hankey G.J., Patel M.R., Stevens S.R., et al. ROCKET AF Steering Committee Investigators. Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or TIA: a subgroup analysis of ROCKET AF. Lancet Neurol. 2012; 11(4): 315-22.
  23. Diamantopoulos A., Forster F., Evers Th. Real-life treatment persistence with newer oral anticoagulants and potential strokes avoided in patients with atrial fibrillation. ESC Congress. 2013 poster P519.
  24. Koon-Hou Mak. Coronary and mortality risk of novel oral antithrombotic agents: a meta-analysis of large randomised trials.BMJ Open 2012; 2: e001592 doi: 10.1136/bmjopen-2012-001592.
  25. Liesenfeld K.H., Lehr T., Dansirikul C., Reilly P.A., Connolly S.J., Ezekowitz M.D., et al. Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial. J. Thromb. Haemost. 2011; 9: 2168-75.
  26. Heidbuchel H., et al. EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur. Heart J. 2013; 34(27): 2094-106.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2014 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies